Innate Immunity

Description

Innate immunity is the evolutionary ancient first-line defense system that recognizes and responds to pathogens and cellular damage through pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) and NOD-like receptors. In the brain, innate immunity is primarily mediated by microglia and astrocytes, which detect both pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). A paradigm-shifting discovery is that amyloid-beta itself functions as an antimicrobial peptide (AMP), capable of forming pores in microbial membranes and entrapping pathogens in amyloid cages.

In Alzheimer's disease, the innate immune system appears to be fundamentally dysregulated at multiple levels. Abeta's role as an AMP means that amyloid production may begin as an appropriate innate immune defense against real pathogens (HSV-1, P. gingivalis) or perceived threats (DAMPs from damaged neurons). However, the system becomes pathologically self-perpetuating: necrotic neurons release GM1 ganglioside-Abeta complexes that act as DAMPs, triggering further Abeta production by neighboring neurons in an "electrophysiological identity error" where neurons are mistaken for bacteria based on their damaged membrane profiles. The human cathelicidin LL-37 normally acts as a chaperone preventing Abeta fibrillation, but P. gingivalis gingipains degrade LL-37, breaking this critical immune checkpoint.

The innate immune perspective reframes AD not as a protein misfolding disease but as an immunopathy -- a chronic, self-sustaining innate immune response that has lost its ability to resolve. This has implications for therapy: rather than suppressing immunity broadly, the goal becomes restoring immune homeostasis through approaches like trained immunity (BCG vaccination), antimicrobial peptide augmentation, or metabolic reprogramming of immune cells.

Convergence Nodes

• Neuroimmune Interface -- Innate immune effectors (complement, TREM2, TLRs) drive synaptic pruning and phagocytosis
• Compensatory Paradigm Nexus -- Abeta as antimicrobial peptide represents a protective response that becomes pathologically reinforced
• APOE4 Hub -- APOE4 alters innate immune receptor signaling and pathogen susceptibility

Prize Entrants

• Donald Weaver -- Reclassified Abeta as innate immune cytokine; proposed AD as autoimmune disorder where neurons are mistakenly attacked due to electrophysiological identity error
• Annalise Barron -- Identified LL-37 cathelicidin as Abeta chaperone; showed P. gingivalis gingipains break the LL-37 checkpoint; linked vitamin D and gut-brain axis to innate immune defense
• Zhen Huang -- Demonstrated Abeta monomer/oligomer duality in innate immune signaling; showed monomer depletion disinhibits microglial TNF-alpha
• Ruth Itzhaki -- Framed HSV-1 as trigger for Abeta antimicrobial response; showed APOE4 carriers have heightened viral susceptibility
• Stephen Dominy -- Identified P. gingivalis as specific pathogen trigger; showed gingipain sabotage of autophagy as molecular mechanism
• Carina Clawson -- Described ceramide-mediated innate immune amplification through BACE1 stabilization and Abeta-ceramide feedback loops

External Scientists

• Rudolph Tanzi -- Co-discoverer (with Moir) of Abeta as antimicrobial peptide
• Robert Moir -- Demonstrated Abeta antimicrobial activity against bacteria, fungi, and viruses
• Michael Heneka -- NLRP3 inflammasome in innate immune activation in AD

Key Open Questions

• If Abeta is an antimicrobial peptide, should anti-amyloid therapies be reconsidered as potentially immunosuppressive?
• Can trained immunity approaches (BCG, immune checkpoint modulation) restore innate immune homeostasis without exacerbating neuroinflammation?
• Is there a specific pathogen (HSV-1, P. gingivalis, or other) that serves as the primary trigger, or does the innate immune response become self-sustaining independently of the original stimulus?
• How does the LL-37 checkpoint interact with APOE genotype and vitamin D status to modulate AD risk?